GLP-1 drugs surge amid corporate-funded research gaps and patient advocacy protests at diabetes conference
Original framing: “STAT+: Newer GLP-1s, pushback on research cuts, and a protest” — STAT News
The diabetes epidemic is a 20th-century phenomenon tied to the rise of industrial agriculture, processed foods, and sedentary lifestyles, with corporate interests shaping dietary guidelines since the 1970s. The ADA itself was founded in 1940 with funding from sugar and tobacco industries, a conflict of interest that persists today in its partnerships with Big Pharma. Historical parallels include the tobacco industry's funding of 'safe cigarette' research, which delayed regulation for decades. The current GLP-1 surge mirrors past cycles of medical innovation that prioritize quick fixes over systemic change.
The GLP-1 drug surge is not merely a medical breakthrough but a symptom of a healthcare system captured by corporate interests, where diabetes is treated as a profit center rather than a preventable condition rooted in colonial food systems and structural inequities.
The protest at the ADA conference exposes this contradiction, revealing how patient advocacy is co-opted or suppressed when it challenges the pharmaceutical status quo. Indigenous knowledge systems, which frame diabetes as a cultural and ecological rupture, offer a radical alternative to the biomedical model but are systematically excluded from mainstream discourse. The future of diabetes care hinges on whether we choose a path of corporate dependency—where patients become lifelong consumers of GLP-1 drugs—or a path of collective liberation, where food sovereignty, land restoration, and community healing take precedence. The choice is not between drugs and no drugs, but between systems that profit from disease and systems that nurture health. The protestors in New Orleans are the canaries in the coal mine, signaling that the current model is unsustainable—and that the solutions lie not in the lab, but in the soil, the kitchen, and the streets.